Phase 3 Multiple Sclerosis Clinical Trials
21 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 21 trials
Recruiting
Phase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Multiple Sclerosis
Sanofi160 enrolled9 locationsNCT07325292
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled37 locationsNCT07225504
Recruiting
Phase 3
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Sandoz175 enrolled40 locationsNCT06847724
Recruiting
Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen444 enrolled105 locationsNCT06700343
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled386 locationsNCT06141473
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.360 enrolled42 locationsNCT07211633
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled46 locationsNCT05877963
Recruiting
Phase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Multiple Sclerosis
Sanofi900 enrolled338 locationsNCT06141486
Recruiting
Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled86 locationsNCT06846281
Recruiting
Phase 3
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Multiple Sclerosis
Hoffmann-La Roche500 enrolled44 locationsNCT06675955
Recruiting
Phase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Celgene194 enrolled33 locationsNCT06408259
Recruiting
Phase 3
RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.
Multiple SclerosisRelapsing Remitting Multiple Sclerosis
Rennes University Hospital386 enrolled23 locationsNCT05758831
Recruiting
Phase 3
Impact of Annual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS,After 2 Years of Initial Treatment, on Freedom From Radiological Disease Activity at Two Years: a Multicenter Randomized Controlled Non-inferiority Trial
Multiple Sclerosis
Fondation Ophtalmologique Adolphe de Rothschild244 enrolled11 locationsNCT05999604
Recruiting
Phase 3
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
Relapsing Multiple SclerosisRelapsing Remitting Multiple SclerosisSecondary Progressive Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)156 enrolled22 locationsNCT04047628
Recruiting
Phase 3
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis (RRMS)
Biocad292 enrolled1 locationNCT07321093
Recruiting
Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Multiple Sclerosis (MS) Primary Progressive
Zenas BioPharma (USA), LLC705 enrolled2 locationsNCT07067463
Recruiting
Phase 3
Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple Sclerosis
Multiple SclerosisInternuclear Ophthalmoplegia
Amsterdam UMC, location VUmc80 enrolled1 locationNCT05338450
Recruiting
Phase 3
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Celltrion512 enrolled1 locationNCT05906992
Recruiting
Phase 3
Disease Modifying Therapies Withdrawal in Inactive Secondary Progressive Multiple Sclerosis Patients Older Than 50 Years (STOP-I-SEP)
Multiple Sclerosis
Rennes University Hospital250 enrolled27 locationsNCT03653273
Recruiting
Phase 2Phase 3
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
Multiple SclerosisMultiple Sclerosis, Secondary Progressive
Institute of Psychiatry and Neurology, Warsaw188 enrolled1 locationNCT05961644